Regeneron Pharmaceuticals Inc.’s (REGN) Pozelimab, an investigational fully human monoclonal antibody designed to block the activity of complement factor C5, a protein involved in complement system activation, awaits the FDA decision on August 20, 2023.Pozelimab is proposed as a treatment for adults and children as young as 1 year of age with CHAPLE disease.CHAPLE disease, also known as CD55 deficiency with Hyperactivation of complement, Angiopathic thrombosis and Protein Losing Enteropathy, is an ultra-rare and life-threatening hereditary immune disease, driven by an overactivation of the complement system.There are currently no approved treatments for CHAPLE disease. REGN closed Friday’s (Jul.28, 2023) trading at $746.10, up 0.19%.